Introduction {#s1}
============

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of mature T-cell neoplasms, comprising 10--15% of all cases of non-Hodgkin lymphoma cases in the United States ([@B1]), with at least 29 subtypes recognized by the revised 2016 World Health Organization classification of lymphoid neoplasms ([@B2]). PTCL generally carries a poor prognosis. The complex pathobiology of these disorders is well-reflected in their heterogeneous clinical, histological, and immunophenotypic features. Advances in the genome sequencing and gene expression profiling (GEP) of PTCL have improved our understanding of its molecular pathobiology, and a precise definition of its molecular background has revealed novel therapeutic targets. In this review, we focus on the recently discovered somatic genetic abnormalities of and emerging therapies for 3 of the most common PTCL subtypes: angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and PTCL-not otherwise specified (PTCL-NOS) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). Germline mutations are beyond the scope of this review.

Angioimmunoblastic T-Cell Lymphoma and Other Nodal Lymphomas of Follicular T Helper Cell Origin {#s2}
===============================================================================================

AITL is the one of the most common PTCL entities, accounting for \~20--30% of all PTCL cases in the United States ([@B3]). The AITL cell originates from CD4^+^ T follicular helper cells (TFHs) ([@B4]). AITL is associated with B-cell lymphoproliferative disorders and a constitutively activated immune system ([@B5]). The prognosis of patients with AITL is poor, with a 5-year overall survival (OS) rate of 33% ([@B5]). There has been no significant improvement in OS in the last 3 decades ([@B6]).

Recent advances in next-generation sequencing have led to the discovery of recurrent mutations in AITL. The most frequently reported somatic mutations include alterations in epigenetic regulators; ras homolog family member A (*RHOA*); and T-cell receptor (TCR) signaling pathway molecules ([Table 1](#T1){ref-type="table"}).

###### 

Genetic aberrations reported in the 3 most common types of PTCL.

  **Gene**                                                  **Frequency, %**      **Potential Targets**                     **Examples**                                                 **Reference**
  --------------------------------------------------------- --------------------- ----------------------------------------- ------------------------------------------------------------ ----------------------------------
  **ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA**                                                                                                                                                 
  **RAS super family**                                                                                                                                                                   
  *RHOA^*G*17*V*^*                                          50--72                Multikinase inhibitors; PI3K inhibitors   dasatinib; duvelisib                                         ([@B7]--[@B10])
  **Epigenetic regulators**                                                                                                                                                              
  *TET2*                                                    47--86                HMAs, HDACis                              5-azacytidine;romidepsin[^\*^](#TN1){ref-type="table-fn"}    ([@B7], [@B9], [@B11], [@B12])
  *DNMT3A*                                                  20--48                HMAs, HDACis                              5-azacytidine; romidepsin[^\*^](#TN1){ref-type="table-fn"}   ([@B7], [@B9]--[@B11], [@B13])
  *IDH2^*R172*^*                                            20--45                HMAs, HDACis                              5-azacytidine; romidepsin[^\*^](#TN1){ref-type="table-fn"}   ([@B7], [@B9], [@B11], [@B14])
  **TCR signaling pathway**                                                                                                                                                              
  *PLCγ*                                                    14                    Calcineurin inhibitors                    cyclosporine A                                               ([@B13])
  *CD28[^\#^](#TN2){ref-type="table-fn"}*                   9--11                 Calcineurin inhibitors                    cyclosporine A                                               ([@B15], [@B16])
  *FYN*                                                     3--4                  Calcineurin inhibitors                    cyclosporine A                                               ([@B10], [@B15])
  *VAV1*                                                    5                     RAC1 inhibitor                            azathioprine                                                 ([@B15])
  **Structural alteration**                                                                                                                                                              
  *CTLA4-CD28* fusion                                       58                    Anti-CTLA4 immunotherapy                  ipilimumab                                                   ([@B17])
  *ICOS-CD28* fusion                                        5                                                                                                                            ([@B16])
  **ANAPLASTIC lARGE CELL LYMPHOMA**                                                                                                                                                     
  **Transcription factor**                                                                                                                                                               
  *STAT3*                                                   3                     JAK/STAT inhibitors                       ruxolitinib                                                  ([@B18])
  *JAK1*                                                    8                     JAK/STAT inhibitors                       ruxolitinib                                                  ([@B18])
  *JAK1+STAT3*                                              7                     JAK/STAT inhibitors                       ruxolitinib                                                  ([@B18])
  **Epigenetic regulators**                                                                                                                                                              
  *TET2*                                                    33                    HMAs, HDACis                              5-azacytidine, romidepsin[^\*^](#TN1){ref-type="table-fn"}   ([@B19])
  *DNMT3A*                                                  17                    HMAs, HDACis                              5-azacytidine, romidepsin[^\*^](#TN1){ref-type="table-fn"}   
  **TCR signal pathway**                                                                                                                                                                 
  *VAV1*                                                    11                    RAC1 inhibitors                           azathioprine                                                 ([@B20])
  **Tumor suppressor**                                                                                                                                                                   
  *DUSP22*                                                  30                                                                                                                           ([@B21], [@B22])
  *TP53[^\#^](#TN2){ref-type="table-fn"}*                   42                                                                                                                           ([@B21], [@B22])
  *PRDM1[^\#^](#TN2){ref-type="table-fn"}*                  35                                                                                                                           ([@B21], [@B22])
  **Structural alteration**                                                                                                                                                              
  *ROS1*                                                    N/A                   JAK/STAT3 inhibitors                      ruxolitinib                                                  ([@B18])
  *TYK2*                                                    N/A                   JAK/STAT3 inhibitors                      ruxolitinib                                                  ([@B18])
  *ERBB4*                                                   24                    ERB Kinase Inhibitors                     cetuximab, gefitinib                                         ([@B23])
  *COL29A1*                                                 24                    ERB Kinase Inhibitors                     cetuximab, gefitinib                                         ([@B23])
  *TP63* rearrangement[^\#^](#TN2){ref-type="table-fn"}     8                                                                                                                            ([@B21])
  **PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED**                                                                                                                                
  **Epigenetic regulator**                                                                                                                                                               
  *TET2*                                                    38--49                HMAs, HDACis                              romidepsin\*, belinostat\*, azacytidine                      ([@B9], [@B12], [@B24]--[@B26])
  *DNMT3A*                                                  5--27                 HMAs, HDACis                              romidepsin\*, belinostat\*, azacytidine                      ([@B9], [@B12], [@B24]--[@B26])
  *IDH2*                                                    0--8                  HMAs, HDACis                              romidepsin\*, belinostat\*, azacytidine                      ([@B9], [@B12], [@B24]--[@B26])
  *KMT2C KMT2D*                                             8 2--20               HMAs, HDACis                              romidepsin\*, belinostat\*, azacytidine                      ([@B9], [@B12], [@B24]--[@B26])
  *SETD1B SETD2 KDM6A CREBBP*                               5 3--10 1--11 4--16   HMAs, HDACis                              romidepsin\*, belinostat\*, azacytidine                      ([@B9], [@B12], [@B24]--[@B27])
  **Tumor suppressor**                                                                                                                                                                   
  *TP53[^\#^](#TN2){ref-type="table-fn"}*                   7--16                                                                                                                        ([@B25], [@B28], [@B29])
  *ATM*                                                     4--16                                                                                                                        
  **TCR signaling pathway**                                                                                                                                                              
  *RHOA^G17V^*                                              7--26                 Multikinase inhibitors; PI3K inhibitors   duvelisib, tenalisib                                         ([@B9], [@B10], [@B24]--[@B26])
  *FYN*                                                     2--3                  SYK inhibitors                            fostamatinib, entospletinib                                  ([@B9], [@B10], [@B24]--[@B26])
  **Structural alteration**                                                                                                                                                              
  *VAV1* fusion                                             18                    RAC1 inhibitor                            azathioprine                                                 ([@B17], [@B20], [@B30], [@B31])
  *CTLA4-CD28* fusion                                       23                    Anti-CTLA4 immunotherapy                  ipilimumab                                                   ([@B17], [@B20], [@B30], [@B31])
  *ITK-SYK* fusion                                          17--18                SYK inhibitors                            fostamatinib, entospletinib                                  ([@B17], [@B20], [@B30], [@B31])

denotes FDA approved therapy for PTCL;

*denotes poor prognostic indicators*.

*HDACis, histone deacetylase inhibitors; HMAs, Hypomethylating agents; PI3K, phosphoinositide 3-kinase; SYK, spleen tyrosine kinase*.

Epigenetic Regulators
---------------------

Tet methylcytosine dioxygenase 2 (*TET2*), DNA methyltransferase 3α (*DNMT3A*), and mitochondrial isocitrate dehydrogenase 2 (*IDH2*) genes participate in the regulation of DNA methylation/hydromethylation. Mutations in *TET2* and *DNMT3A* are associated with hypermethylation and dysregulated gene expression ([@B11], [@B32]), and the *IDH2*^*R*172^ mutant confers neo-enzymatic activity, producing oncometabolite D-2 hydroxyglutarate (D-2-HG). The accumulation of D-2-HG inhibits both histone lysine demethylase and the DNA hydroxylase in the TET family ([@B33]). Interestingly, the high co-occurrence of *TET2* and *IDH2*^*R*172^ mutations in AITL suggests a synergistic effect, by which these genes upregulate follicular T helper--associated genes and downregulate genes associated with T~H1~, T~H2~, and T~H17~ cells ([@B7], [@B19]).

Epigenetic modulating agents are promising targets for patients with relapsed AITL. 5-azacytidine, has induced a sustained response in selected patients with *TET2*-mutated relapsed/refractory AITL ([@B34]). A similar response is reported with romidepsin ([@B35]).

TCR Signaling Pathway
---------------------

The *RHOA*^*G*17*V*^ mutation is common in AITL. RHOA is a small GTPase that mediates T-cell migration, polarity, and thymocyte development ([@B36]). Glycine at RHOA residue 17 is critical for GTP binding. Thus, the substitution of Valine leads to a loss of GTPase activity ([@B8]). It was initially believed that the *RHOA*^*G*17*V*^ mutation played an oncogenic role by disrupting the classical RHOA signaling. However, a recently reported p.K18N mutant in AITL is associated with higher GTP binding capacity ([@B15]). This phenomenon is explained by the RHOA-VAV1 signaling pathway. VAV1, a guanine exchange factor protein, functions as an adaptor to facilitate and activate the TCR proximal signaling complex. The binding of G17V RHOA to VAV1 augments VAV1\'s adaptor function, resulting in an accelerated TCR signaling. An isolated VAV1 mutation has also been identified in AITL ([@B37]). Dasatinib blocked accelerated VAV1 phosphorylation and TCR signaling *in vitro* and improved the overall survival of the mice model ([@B37]).

In preclinical models, the expression of RHOA^G17V^ induced TFH cell specification, upregulated the inducible co-stimulator (ICOS), and increased phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase signaling. PI3K inhibitors efficiently inhibited TET2-/-RHOA G17V tumor proliferation ([@B38]).

Other TCR-related mutations in AITL include *PLCG1, CD28*, and *FYN*. *CD28* is the primary costimulatory receptor in T cells and induces sustained T-cell proliferation and cytokine production. The presence of *CD28* mutations correlates with a poor prognosis ([@B16]). Cyclosporine A, a calcineurin inhibitor that blocks TCR signaling, effectively prevented the progression of AITL ([@B39], [@B40]). Two structural changes, *CTLA4-CD28* ([@B17]) and *ICOS-CD28* fusion genes ([@B16]), have also been described. Ipilimumab, an anti-CTLA4 immunotherapy, is a potential treatment for the *CTLA4-CD28* fusion gene.

Multistep Tumorigenesis Model
-----------------------------

To account for the complex genomic landscape of AITL, a multistep tumorigenesis model was proposed ([@B41]--[@B43]). The premalignant hematopoietic progenitor cells harboring mutations (e.g., *TET2* and *DNMT3A*) are predisposed to the development of blood cancer, and the acquisition of second-hit mutations (e.g., *RHOA*^*G*17*V*^ and *IDH2*^*R*172^) in a subclone of TFH cells eventually leads to AITL. This model is supported by the detection of *TET2* and *DNMT3A* mutations in tumor-free peripheral blood cells, bone marrow cells, and hematopoietic progenitors, whereas *RHOA* and *IDH* mutations are specific to malignant cells from AITL tumors ([@B13]).

Nodal T-Cell Lymphomas With TFH Phenotype as a Newly Proposed Group of PTCL
---------------------------------------------------------------------------

Together with AITL, nodal PTCL with TFH phenotype and follicular T-cell lymphoma (F-PTCL) belong to a newly proposed group of PTCL called "nodal T-cell lymphomas with TFH phenotype," described in the 2016 revised WHO classification ([@B2], [@B44]). This change reflects the observation that a subset of PTCLs expresses TFH-associated markers ([@B45], [@B46]). Interestingly, this subset shares common genetic abnormalities with AITL ([@B9], [@B10], [@B12], [@B14], [@B24], [@B32]). The analysis of 94 cases of AITL, 5 cases of F-PTCL, and 16 cases of nodal PTCL with TFH phenotype supported this grouping ([@B13]). These entities shared not only disease severity and prognosis, but also global and specific gene expression patterns. They had similar mutation frequencies in *TET2, RHOA, DNMT3A*, with the exception of *IDH2*^*R*172^ mutation, which was restricted to AITL.

We recommend routine screening of any PTCL-NOS for TFH markers and assigning them to this new category when at least 2 TFH markers are simultaneously detected on the neoplastic cells.

ALCL {#s3}
====

ALCL accounts for \~12% of PTCL cases in the United States ([@B3]). ALCL is characterized by CD30 positivity. The 2016 revision of WHO classification system for lymphoid neoplasms recognizes 4 subtypes of ALCL: ALK^+^ ALCL, ALK^−^ ALCL, primary cutaneous, and breast implant--associated ALCL ([@B44], [@B47]). The differentiation between ALK^+^ and ALK^−^ subtypes has formed the backbone of the current classification system.

ALK^+^ ALCL
-----------

ALK^+^ ALCL commonly presents in young populations, generally within the first 3 decades of life and carries a significantly better prognosis (5-year OS, 70--85%) than ALK^−^ ALCL (5-year OS, 30--49%) ([@B48]). The presence of *ALK* gene rearrangements in ALK^+^ ALCL, most commonly translocation t(2;5)(p23;q35), results in the fusion of nucleophosmin (NPM1) and ALK ([@B49]). Anti-ALK antibodies can identify the proteins produced by NPM1/ALK transcripts based on staining patterns. ALK^+^ ALCL expressed ALK in nucleus and cytoplasm; conversely, variant fusions lacked nuclear ALK-staining ([@B50]).

*ALK* gene rearrangements often occur within the intron, between exons 19 and 20, allowing the intracytoplasmic domain of ALK to fuse with NPM1. The dimerization domain auto-phosphorylates the ALK catalytic domain and activates multiple downstream signaling pathways, including PI3K/AKT, RAS/ERK, and JAK/STAT ([@B51]).

NPM1-ALK cell lines express STAT3 phosphorylated on serine residue 727 and tyrosine residue 705 and increase STAT3 expression at the transcriptional level. Although JAK3 is phosphorylated, its binding is not essential for STAT3 activity. NPM-ALK fusion transcripts could activate STAT3 directly ([@B52]). This activation is important, as STAT3 is integral to cell survival by controlling the transcription of numerous apoptosis-regulating proteins, such as cyclin D1, Bcl-X, Bcl-XL, and c-Myc ([@B53]). Although NPM1/ALK fusion transcripts are the most common rearrangements in ALK+ ALCL, other rearrangements, such as TPM3 (1q25), ATIC (2q35), TFG (3q21), TPM4 (19p13.1), MYH9 (22q11.2), RNF213 (17q25), TRAF1 (9q33.2), CLTC (17q23), and MSN (Xq11), have also been reported ([@B54]).

ALK^−^ ALCL
-----------

ALK-- ALCL was upgraded from a provisional to a definite entity in the revised 2016 WHO classification ([@B55]). It is difficult to differentiate between ALK-- ALCL and PTCL-NOS based on CD30 positivity ([@B20]). To better define ALCL from PTCL-NOS, GEP of PTCL-NOS, and ALCL discovered a unique cluster of gene transcripts shared by ALK-- and ALK+ALCLs ([@B56]). We can also distinguish ALK--ALCL from CD30+ PTCL-NOS through clinical outcomes ([@B57], [@B58]). CD30+ PTCL-NOS has a poorer prognosis and requires more aggressive treatment ([@B59], [@B60]). Based on GEP, a 3-gene model (TNFRSF8, BATF3, and TMOD1) was developed to separate ALK-- ALCL from PTCL-NOS, with 97% accuracy ([@B61]).

### Chromosomal Rearrangements of DUSP22 and TP63 as a Differentiating Factor

Two chromosomal rearrangements, *DUSP22* and *TP63*, subclassify ALK^−^ALCL into 3 groups: DUSP22-rearranged, TP63-rearranged, and group without any rearrangement. *DUSP22* rearrangement occurs in 30% of ALK^−^ ALCL patients and is associated with a 5-year OS rate of 80--90%, similar to that of ALK^+^ ALCL (5-year OS, 85%) ([@B62]). It is associated with downregulation of *DUSP22*, which leads to the inhibition of TCR signaling and the promotion of apoptosis ([@B21]). Its unique immunogenic molecular signature, such as DNA hypomethylation, lower expression of PD-1, and higher expression of costimulatory gene *CD58* and HLA Class II likely contributes to its favorable prognosis ([@B63]). Other clinical predictors, such as IPI risk factors, age, and CD3 positivity, also impact prognosis despite *DUSP22* rearrangement ([@B64], [@B65]).

*TP63* rearrangement, the fusion transcript of TBL1XR1/TP63, has similar structural homology to oncogenic deltaNp63 in p53 tumor suppressor pathway and is associated with inferior survival ([@B66]).

A third category, defined as triple-negative (ALK^−^, *DUSP22*^−^, and *TP63*^−^), harbors the remaining 62% of ALK^−^ ALCL cases and has a 5-year OS rate of 42% ([@B67]). Although further validation of this model is needed, *DUSP22* and *TP63* rearrangements may serve as useful biomarkers in prognosis and direct therapy for patients with ALK^−^ ALCL in the future.

### Other Genetic Aberrations in ALK^−^ALCL

As in ALK^+^ ALCL, the JAK/STAT3 pathway is constitutively activated in ALK^−^ ALCL ([@B68]). Recurrent single or convergent somatic mutations and translocations in the *JAK1* and *STAT3* genes are thought to upregulate the STAT3 pathway ([@B18], [@B19]). In addition, the gene fusions involving *ROS1* and *TYK2* in some ALK^−^ ALCLs have led to the activation of STAT3 independent of JAK1 or STAT3 mutations. RNA sequencing has identified the co-expression of truncated *ERBB4* and *COL29A1* in 24% of patients with ALK^−^ ALCL ([@B23]). These *ERBB4*-truncated forms are potentially oncogenic, and *ERBB4* inhibition can partially arrest cell growth and stop disease progression. These transcripts were not observed in ALK^+^ ALCL or PTCL-NOS patients. More recently, losses at 6p21 and 17p13 were identified in ALK^−^ ALCL using single nucleotide polymorphism arrays ([@B22], [@B69]). These losses correlated with the losses of *TP53* and *PRDM1* and poor prognoses.

PTCL-NOS {#s4}
========

PTCL-NOS is the most common subtype of PTCL, accounting for 30--50% of PTCL cases in the United States ([@B3], [@B70]). Patients are diagnosed with PTCL-NOS if they do not meet the diagnostic criteria of other PTCL subtypes as per WHO 2016 revision ([@B2], [@B70]). As a diagnosis of exclusion, PTCL-NOS comprises a heterogeneous group of diseases with diverse cells of origin and presents with different cytogenic, molecular, and morphological phenotypes. This heterogeneity makes classification and treatment of the disease difficult. With the standard anthracycline-based chemotherapy, complete response rates range from 40 to 60%, and 5-year OS rates range from 30 to 40% ([@B71], [@B72]).

GATA3 and TBX21 Expression as a Differentiating Factor in PTCL-NOS
------------------------------------------------------------------

PTCL-NOS can be categorized based on *GATA3* and *TBX21* expression *and* T helper 1 and T helper 2 cell differentiation regulators ([@B73], [@B74]). PTCL-NOS cases with high expression of *TBX21* have a tumor microenvironment gene signature, whereas those of *GATA3* have a cytotoxic gene signature with poorer outcomes ([@B75]). The greater genomic complexity associated with *GATA3* is characterized by frequent loss of tumor suppressor genes on the CDKN2A/B-TP3 axis and PTEN-PI3K pathways as well as genetic gains and amplification of *STAT3* and *MYC*. Immunohistochemistry (IHC) algorithm can be used to identified the two subtypes and add in risk stratification for clinical trials ([@B76]).

Watatani\'s group studied the relation between PTCL-NOS with TFH phenotype and *GATA3/TBX21* expression using GEP ([@B25]). PTCL-NOS without TFH phenotype often has mutations in *TP53* and/or *CDKNA2A* genes, which can cause chromosomal instability and mediate immune escape and transcriptional regulations. Those mutations potentially explain the worse outcomes among patients with PTCL-NOS without TFH phenotype as compared with those with TFH phenotype. However, there was no difference in *GATA3* and *TBX21* expression in the TFH-related group and in the *TP53/CDKN2A*-altered group.

Other Genetic Aberrations in PTCL-NOS
-------------------------------------

The *FYN* gene encodes a tyrosinase kinase involved in T-cell activation and Src kinase inhibition. Dasatinib targeted the Src kinase *in vitro*, and could be a l target for patients with mutations in *FYN* genes ([@B10]). Recurrent loss at 9p21.3 decreases the expression of the cyclin-dependent kinase inhibitors 2A and 2B which are associated with a poorer prognosis ([@B28]). Guanine nucleotide exchange factor *VAV1* encodes a critical component of TCR signaling, and recurrent gene fusion of *VAV1* has also been identified ([@B20]). Recurrent genetic activating mutations and translocations of *VAV1* gene in PTCL-NOS highlighted its role of a drive oncogene in catalytic-dependent (MAPK and JNK) and -independent (NFAT) VAV1 effector pathways ([@B77]). Azathioprine targets cells overexpressing the *VAV1-GSS* fusion protein ([@B20]). *CTLA4-CD28* fusion and mutations in *KMT2C* and *SET1B* (histone methylation) have also been identified ([@B17], [@B27]).

*FAT1* tumor suppressor binds to β-catenin and inhibits nuclear localization, thus inhibiting cell growth. The recurrent mutations in *FAT1* tumor suppressor gene were seen in 39% cases of PTCL-NOS and is associated with inferior outcome ([@B29]).

With new differentiating factors such as TFH phenotype, *GATA3/TBX21* expression, we may expect PTCL-NOS to be better categorized, which could provide more insight into defining targetable molecular pathways and developing novel therapeutic strategies for PTCL-NOS patients.

Clinical Implications and Personalized Medicine {#s5}
===============================================

Recent advances in genome sequencing and GEP have led to the identification of commonly dysregulated pathways, especially enhanced T-cell signaling pathways, in all of the 3 most common nodal subtypes of PTCL. Despite similarities in genomic profiles, the interaction between various pathways might play a role in determining divergent cell differentiation and tumorigenesis. For example, some mutations in the epigenetic modifier genes are similar between AITL and myeloid neoplasms; however, the mutation patterns are different. *TET2* and *IDH2* mutations are mutually exclusive in acute myeloid leukemia. In contrast, *IDH2* mutations often cooccur with *TET2* mutations in AITL ([@B19], [@B78]). These different mutation patterns suggest that the interaction between *IDH2* and *TET2* mutations possibly lead to the development of a TFH phenotype.

The different patterns of molecular signature profiles can help us to identify and to reclassify AITL and ALCL from PTCL-NOS in cases that do not meet morphological criteria ([Figure 1](#F1){ref-type="fig"}). Iqbal et al. reclassified 14% of PTCL-NOS cases as AITL via GEP using the 3 prominent AITL signatures: B-cell signature, follicular dendritic-cell signature, and cytokine signature ([@B79]). This reclassification was then confirmed by the presence of the *IDH2*^R172^ mutation. The presence of the *RHOA*^G17V^ mutation helped to identify nodal T-cell lymphomas with TFH phenotype, as this mutation key in TFH cell speciation and AITL transformation ([@B38]). *ITK-SYK* gene fusion could potentially differentiate a subset of PTCL-NOS patients with TFH phenotype from those with AITL ([@B30], [@B31], [@B80], [@B81]) ([Figure 1](#F1){ref-type="fig"}).

![Unique and shared mutations identified in the 3 most common types of PTCL. The Venn diagram above showed the most frequently encountered genomic abnormalities in 3 most common types of peripheral T-cell lymphoma: angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). TET2 and DNMT3A mutations are seen in all 3 major subtypes.](fonc-10-00898-g0001){#F1}

Agnelli et al. reclassified 11% of PTCL-NOS cases as ALCL using a 3-gene model (*TNFRSF8, BATF3*, and *TMOD1*) with 97% accuracy ([@B61]). Similarly, lack of *ERBB4* transcript in other PTCL subtypes could help to confirm the diagnosis of ALK^−^ ALCL ([@B23]) ([Figure 1](#F1){ref-type="fig"}).

Furthermore, many mutations have been associated with the prognosis of PTCL. The mutations associated with a poor prognosis include *CD28* mutations in AITL ([@B16]); *TP63* rearrangement ([@B21]), loss of *TP53*, and loss of *PRDM1* ([@B22]) in ALK^−^ ALCL; *GATA3* ([@B75]), *TP53*, and/or *CDKN2A* ([@B25]) in ALK^−^ ALCL; and alterations in histone methyltransferase genes *KMT2A, KMT2B*, or *KDM6A* ([@B82]) and *FAT1* ([@B29]) in PTCL-NOS. The mutations associated with a favorable prognosis include the presence of *DUSP22* in ALK^−^ ALCL ([@B21]).

Potential Therapeutic Targets {#s6}
=============================

Most PTCL subgroups have median OS rates of 1--3 years, except for ALK^+^ ALCL ([@B3]). Only a small portion (20%-40%) of patients with PTCL achieve long-term survival ([@B6]). During the past 3 decades, long-term survival has not been significantly improved by available therapies ([@B83]). Fortunately, a greater understanding of the pathogenesis of the major PTCL subtypes has led to the identification of potentially actionable biologic pathways, especially activating pathways. Novel targeting therapies are now available for clinical studies ([Table 1](#T1){ref-type="table"}).

Epigenetic modulators, such as romidepsin (NCT03141203, NCT00426764), chidamide (NCT03268889), and HBI-8000 (NCT02953652), are currently being investigated in clinical trials for PTCL, either as a monotherapy or in conjunction with other therapies.

The T-cell signaling pathway also has multiple candidate therapies: multikinase inhibitors, such as dasatinib (NCT01609816, NCT01643603), for PTCL; PI3K inhibitors, such as duvelisib (NCT03372057) and copanlisib (NCT03052933), for PTCL; an anti-ICOS monoclonal antibody in ICOS-PI3K pathways, MEDI−570 (NCT02520791), for the follicular variant of PTCL-NOS and AITL; and a CTLA-4 inhibitor, such as ipilimumab, for CLA-CD28 fusion-positive tumors.

The transcription factor NF-κB pathway is differentially activated in PTCL, especially in the AITL subtype ([@B79]). Bortezomib, a proteasome inhibitor with NF-κB inhibitory activity, has shown early promise in the treatment of adult T-cell lymphoma ([@B84]). An additional clinical study on bortezomib is currently underway (NCT04061772), as well as studies on ixazomib, a drug similar to bortezomib (NCT03547700).

The JAK-STAT3 pathways are sometimes aberrantly activated in PTCL, especially in ALCL and in some cases of PTCL-NOS. JAK inhibitors, such as ruxolitinib, were previously used extensively for myeloid disorder and are currently under investigation for treating patients with PTCL (NCT01431209).

Another promising target is SYK, a receptor-associated tyrosine kinase expressed in 94% of all PTCL patients ([@B85]). The SYK inhibitor R406 effectively caused apoptosis and inhibited cell growth in preclinical studies ([@B86]). SYK inhibitors, such as entospletinib, are promising potential agents.

The ALK-1 inhibitor crizotinib was used in patients with relapsed pediatric ALK^+^ ALCL, with a complete response rate of 83% (NCT00939770) ([@B87]). For ALK^+^ ALCL resistant to crizotinib, platelet-derived growth factor receptor-β (PDGFRB) blockade is potentially effective. Imatinib, acting on PDGFRA and PDGFRB blockade, induced a complete remission in a late stage NPM-ALK^+^ ALCL patient. As suggested in murine model, ALK promotes the expression of activator protein 1 family members JUN and JUNB, which subsequently promote tumor dissemination through PDGFRB regulation ([@B88]).

Other targeted agents tested in PTCL include BCL2 inhibitors (e.g., venetoclax \[NCT03552692\]); monoclonal antibodies targeting CD2 (e.g., siplizumab \[NCT01445535\]); CCR4 monoclonal antibodies (e.g., mogalizumab \[NCT01611142\]); *FYN* inhibitors; CD30 antibody drug conjugates (e.g., brentuximab \[NCT01716806, NCT03496779\]); ERB kinase inhibitors; VGEFR-2 inhibitors (e.g., apatinib \[NCT03631862\]); and PD-1 and PD-L1 inhibitors for immune modulation (e.g., pembrolizumab \[NCT02535247\], nivolumab \[NCT03586999\], durvalumab \[NCT03161223\], and avelumab \[NCT03046953\]).

Currently, novel therapies are being developed rapidly, and personalized medicine is made possible through commercial gene sequencing. The genetic heterogeneity in PTCL requires an individualized therapeutic approach that uses agents that specifically target genetic abnormalities or oncogenic pathways found in patients\' tumors. More rationally designed clinical trials enrolling patients with specific genetic alterations are needed to provide higher response rates and more sustained responses. In the context of genome sequencing and GEP, targeted and personalized therapies will likely provide the best clinical outcomes in patients with PTCL in the near future.
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